Tenax Therapeutics Inc
TENX6.100USD
-0.120-1.93%
取引時間 （ET）15分遅れの株価
24.22M時価総額
損失額直近12ヶ月PER
詳細情報 Tenax Therapeutics Inc 企業名
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
企業情報
企業コードTENX
会社名Tenax Therapeutics Inc
上場日Oct 28, 1993
最高経営責任者「CEO」Mr. Christopher T. (Chris) Giordano
従業員数4
証券種類Ordinary Share
決算期末Oct 28
本社所在地101 Glen Lennox Drive
都市CHAPEL HILL
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号27517
電話番号19198552100
ウェブサイトhttp://www.tenaxthera.com/
企業コードTENX
上場日Oct 28, 1993
最高経営責任者「CEO」Mr. Christopher T. (Chris) Giordano
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
2.65K
--
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Mr. Thomas A. (Tom) Mcgauley
Mr. Thomas A. (Tom) Mcgauley
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Robyn M. Hunter
Ms. Robyn M. Hunter
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
2.65K
--
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Mr. Thomas A. (Tom) Mcgauley
Mr. Thomas A. (Tom) Mcgauley
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Fri, May 16
更新時刻: Fri, May 16
株主統計
種類
株主統計
株主統計
比率
RTW Investments L.P.
9.12%
The Lind Partners, LLC
9.04%
Dellora Investments LP
8.46%
BVF Partners L.P.
8.18%
Millennium Management LLC
5.63%
Other
59.56%
株主統計
株主統計
比率
RTW Investments L.P.
9.12%
The Lind Partners, LLC
9.04%
Dellora Investments LP
8.46%
BVF Partners L.P.
8.18%
Millennium Management LLC
5.63%
Other
59.56%
種類
株主統計
比率
Hedge Fund
30.53%
Investment Advisor/Hedge Fund
18.96%
Venture Capital
10.04%
Investment Advisor
9.19%
Research Firm
2.85%
Individual Investor
0.23%
Other
28.19%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
58
2.98M
71.81%
+994.85K
2025Q1
58
2.74M
66.20%
+755.49K
2024Q4
56
1.98M
58.13%
+213.72K
2024Q3
58
1.98M
66.48%
+633.55K
2024Q2
48
161.28K
18.23%
+129.16K
2024Q1
48
149.68K
17.63%
+121.80K
2023Q4
43
26.36K
16.08%
+6.23K
2023Q3
45
17.13K
13.16%
+882.00
2023Q2
48
14.32K
12.38%
-2.77K
2023Q1
49
16.81K
20.77%
+6.69K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
RTW Investments L.P.
378.35K
9.12%
+378.35K
--
Mar 31, 2025
The Lind Partners, LLC
375.00K
9.04%
+305.00K
+435.71%
Sep 30, 2024
Dellora Investments LP
351.07K
8.46%
--
--
Mar 05, 2025
BVF Partners L.P.
339.55K
8.18%
--
--
Mar 31, 2025
Millennium Management LLC
233.62K
5.63%
+206.99K
+777.40%
Jun 26, 2025
VR Adviser, LLC
208.33K
5.02%
--
--
Mar 31, 2025
Vivo Capital, LLC
208.33K
5.02%
--
--
Mar 31, 2025
Integral Health Asset Management, LLC
167.00K
4.03%
+167.00K
--
Mar 31, 2025
Janus Henderson Investors
166.67K
4.02%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
117.83K
2.84%
+45.66K
+63.27%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
DFA Dimensional US Sustainability Core 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Jan 04, 2023
Merger
20<1
Jan 04, 2023
Merger
20<1
日付
種類
比率
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Dec 29, 2023
Merger
80<1
Jan 04, 2023
Merger
20<1
Jan 04, 2023
Merger
20<1
Jan 04, 2023
Merger
20<1
Jan 04, 2023
Merger
20<1
